Shield Therapeutics, a pharmaceutical company focusing on iron deficiency treatments, has reported a significant increase in revenues for the year 2023. The company’s sales of its Accrufer/Feraccru iron deficiency treatment surged in the US market, resulting in revenues reaching US$17.5 million. This represents a remarkable 2.8 times increase compared to the previous year, with US sales of Accrufer soaring over three times to US$11.6 million.
Despite the growth in revenues, Shield Therapeutics reported operating losses of US$31.3 million, a decrease from US$49.8 million in the previous year. The company closed the year with cash and equivalents amounting to US$13.9 million.
Shield Therapeutics expressed optimism about the future, stating, “We have dramatically increased the number of prescriptions for Accrufer in the US as we continue to build awareness of the product and enhance our commercial efforts.” The company anticipates further improvement in commercial execution as it approaches the one-year anniversary of its full commercial launch with partner Viatris in 2024.
Looking ahead to 2024, Shield Therapeutics aims to complete its pediatric study, which is expected to create expansion opportunities in both the US and the EU in the following years. By expanding its product portfolio and geographical reach, the company is positioning itself for sustained growth and success in the iron deficiency treatment market.
As Shield Therapeutics continues to advance its commercial initiatives and expand its product offerings, the company is poised to solidify its position as a key player in addressing iron deficiency and improving patient outcomes. With a strong foundation in place and a commitment to innovation, Shield Therapeutics is well-positioned for continued success in the years to come.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.